Clinical Trial Update: A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus [Phase 1]

View source ↗

Summary

A multiple-dose Phase 1 study of Pfizer's PD-0360324 in patients with active Cutaneous Lupus Erythematosus was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Lupus Erythematosus

Drugs mentioned

• PD-0360324

Snippet

Sponsor: Pfizer | Conditions: Cutaneous Lupus Erythematosus | Phase 1 | Status: TERMINATED